Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC, is a geriatric nurse practitioner at City of Hope, working in its Aging Wellness Clinic.
Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC,is a geriatric nurse practitioner at City of Hope, working in its Aging Wellness Clinic, with a special focus on geriatric assessment and implementing a holistic care model among older patients with cancer.
She is receiving this year’s David King Community Clinical Scientist Award at the Association of Community Cancer Centers’ National Oncology Conference for her research and work at the intersection of geriatric care and oncology.
Transcript
Can you discuss big developments or sessions you are excited for at this year’s ACCC National Oncology Conference?
I was looking over the agenda and some of the options that were available. I’m actually really excited for the [session on] social determinants of health through a medical-legal partnership. I feel like we’ve learned so much, especially through the pandemic, and those social determinants, they’re real and they affect outcomes. And now I feel like we’re moving from, “Yes, we know that there are problems and there are things that happen with patients,” and now we can really challenge ourselves and engage and capture a large audience and say, “Okay, now what can we do about it? We know there’s a problem, what can we do about that?”
It’s a great start to look more closely at interventions, barriers, what’s working, what doesn’t work, and I really feel like it’s time to actually move on from, “Yes, we know this is a problem,” to “Yes, we could do something about it now.” And so I think that’s a really big piece that will make a big difference.
I’m also looking forward to the session on expanding cancer treatment through rapid access. It’s an APP [advance practice provider]–led diagnostic clinic. I thought that was pretty cool. Of course, I love the APP-led clinics. We work with a great multidisciplinary team, and we work together. And I feel like our team dynamics are something to definitely be said.
I am also looking forward to a few sessions I saw on self-care. How awesome is it to take care of yourself and take care of others, and really rediscover that joy you started within your field and really try to reinvigorate that? I think that’s another big piece.
And although I do love the hybrid option, I’d like to say that to be in a captive live audience is something that you just can’t take away. I’ve given so many lectures on black screens, and you’re really trying to [capture] what’s going on with the audience—and it can be challenging sometimes. I do like the hybrid option, though, because although it’s great to have a live captive audience, how great is it that you can reach so many people through that hybrid option, as well? So that, that’s a little bit about that.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More